Another example of miRNA therapy in CLL is represented by miR-181a-5p and miR-181b-5p mimics that induce a significant increase in apoptosis when transfected in leukemic B cells from patients with wild type TP53 and reduce leukemic cell expansion by inhibiting TCL1A, AKT, and phosphorylated ERK1 and ERK2 [184]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.